# FDA 483 - AAA Pharmaceutical, Inc. - March 28, 2025

Source: https://www.keypedia.com/records/483/aaa-pharmaceutical-inc/26bf10f7-11e8-4c0a-bc7f-87be30347209

> FDA 483 for AAA Pharmaceutical, Inc. on March 28, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: AAA Pharmaceutical, Inc.
- Inspection Date: 2025-03-28
- Product Type: drugs
- Office Name: New Jersey District Office
- Summary: An FDA inspection of AAA Pharmaceutical, Inc. in Lumberton, NJ, an OTC Drug Repacker/Control Testing Laboratory, revealed significant deficiencies in its stability testing program. The firm failed to follow its written procedures by missing critical stability testing timepoints for drug products. Furthermore, the company's stability study procedures and protocols were found to be inadequate, lacking provisions for missed timepoints and proper justification for early sample pulls.

## Related Documents

- [EIR - 2019-04-03](https://www.keypedia.com/records/eir/aaa-pharmaceutical-inc/95beacdd-197a-4ec8-b3a0-1c5f9e57d249)
- [483 - 2019-04-03](https://www.keypedia.com/records/483/aaa-pharmaceutical-inc/0d44d71b-c849-4775-a502-5679f14945ec)

## Related Officers

- [Tanya R. Syffrard](https://www.keypedia.com/people/tanya-r-syffrard/a78a42b3-6cef-46d9-9698-ec6082956477)

Company: https://www.keypedia.com/companies/aaa-pharmaceutical-inc/a4bd33c0-4805-416c-93f2-55e4116cc481

Office: https://www.keypedia.com/offices/new-jersey-district-office/6ff5e2e9-5cff-44c7-af24-5a55329a8248